Takeda Pharmaceutical Co.

Takeda Pharmaceutical Company Limited è la più grande casa farmaceutica del Giappone e la 12a per fatturato a livello mondiale. La società ha più di 30,000 dipendenti in tutto il mondo e ha fatturato oltre 18 miliardi di dollari nel 2012.
La società si focalizza su queste patologie: ulcera peptica, cancro alla prostata ed endometriosi, malattie urologiche, diabete e ipertensione, malattie respiratorie e infiammatorie, trattamento del dolore.
Takeda Pharmaceuticals è attiva anche nell'oncologia con una società indipendente,
Takeda ha 2 basi principali in Giappone a Osaka e Tokyo. La sua sede Americana si trova a Deerfield, Illinois, mentre quella Europea si trova a Zurigo, Svizzera.
I principali centri di ricerca si trovano a Osaka e Tsukuba, Giappone; San Diego, California; San Francisco, California; Cambridge, Regno Unito; e Singapore.
Gli stabilimenti produttivi sono 18 distribuiti in quattro continenti. (fonte: Wikipedia)
Comunicati Stampa

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein.   (PR Newswire - 27/05/2014) Leggi

Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein.   (PR Newswire - 27/05/2014) Leggi

Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the European Commission has granted Marketing Authorization for once-daily oral Latuda® (lurasidone) for the treatment of schizophrenia in adults. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for Latuda on January 23, 2014. (PR Newswire - 28/03/2014) Leggi

Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

Takeda submitted a Marketing Authorisation Application (MAA) to the EMA in March 2013 for vedolizumab for the treatment of adults with moderately to severely active UC or CD. The CHMP Opinion for vedolizumab will now be reviewed by the European Commission (EC). If the CHMP recommendation is formally adopted by the EC, vedolizumab would be approved for marketing in the 28 member states of the European Union as well as Norway, Iceland and Liechtenstein. (PR Newswire - 21/03/2014) Leggi

Takeda Appoints Giles Platford Head of Emerging Markets

In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin America, Middle East/Africa and South Asia. (PR Newswire - 18/03/2014) Leggi
1 2 3 4 5 6 7 8 9